Integer (NYSE:ITGR) Earns Buy Rating from Benchmark

Benchmark restated their buy rating on shares of Integer (NYSE:ITGR - Free Report) in a research report released on Friday, Benzinga reports. Benchmark currently has a $130.00 price target on the medical equipment provider's stock.

Several other research analysts have also recently issued reports on the stock. KeyCorp raised their target price on shares of Integer from $123.00 to $139.00 and gave the stock an overweight rating in a report on Tuesday, April 9th. CL King began coverage on Integer in a research note on Thursday, March 14th. They set a buy rating and a $137.00 price objective for the company. Finally, Bank of America upgraded shares of Integer from a neutral rating to a buy rating and increased their price objective for the company from $105.00 to $135.00 in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $120.50.

Integer Price Performance

Shares of NYSE:ITGR traded down $1.56 during midday trading on Friday, reaching $109.59. 604,251 shares of the company were exchanged, compared to its average volume of 342,875. The stock has a market cap of $3.67 billion, a PE ratio of 40.74, a price-to-earnings-growth ratio of 1.71 and a beta of 1.10. The business's fifty day moving average is $112.91 and its two-hundred day moving average is $99.57. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. Integer has a one year low of $69.40 and a one year high of $123.99.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.02. Integer had a return on equity of 10.80% and a net margin of 5.68%. The company had revenue of $414.80 million during the quarter, compared to analysts' expectations of $412.78 million. During the same quarter in the previous year, the business earned $0.87 EPS. Integer's revenue was up 9.5% compared to the same quarter last year. As a group, analysts predict that Integer will post 5.31 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB increased its holdings in shares of Integer by 1.7% in the 4th quarter. Handelsbanken Fonder AB now owns 5,837 shares of the medical equipment provider's stock worth $578,000 after acquiring an additional 100 shares during the period. Cornercap Investment Counsel Inc. boosted its position in Integer by 1.0% during the 4th quarter. Cornercap Investment Counsel Inc. now owns 12,014 shares of the medical equipment provider's stock worth $1,190,000 after acquiring an additional 121 shares during the period. Arizona State Retirement System grew its position in Integer by 1.4% during the third quarter. Arizona State Retirement System now owns 9,474 shares of the medical equipment provider's stock valued at $743,000 after purchasing an additional 131 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of Integer by 10.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider's stock worth $141,000 after acquiring an additional 132 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of Integer by 1.5% during the 3rd quarter. Janney Montgomery Scott LLC now owns 9,507 shares of the medical equipment provider's stock worth $746,000 after purchasing an additional 142 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.